Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Targan

Showing results (111-120 of 118) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 118 results.
Inflammatory Bowel Diseases|August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Gut|April 11, 2006
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.
Alimentary Pharmacology & Therapeutics|November 17, 2015
A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variablesC A Siegel, H Horton, L S Siegel, et al.
Gastroenterology|August 28, 1999
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study GroupW J Sandborn, W J Tremaine, D C Wolf, et al.
Gastroenterology|January 1, 1997
A new syndrome of Crohn's disease and pachydermoperiostosis in a familyR F Compton, W J Sandborn, H Yang, et al.
International Journal of Obesity (2005)|May 11, 2016
Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptorD Hoang-Yen Tran, D Hoang-Ngoc Tran, S A Mattai, et al.
Nature Communications|August 10, 2016
A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitisManuel A Rivas, Daniel Graham, Patrick Sulem, et al.
Pageof 12

Showing results (111-120 of 118) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 118 results.
Inflammatory Bowel Diseases|August 23, 2001
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's diseaseW J Sandborn, E V Loftus, J F Colombel, et al.
Gastroenterology|April 21, 2001
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trialW J Sandborn, B G Feagan, S B Hanauer, et al.
Gut|April 11, 2006
Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trialG Van Assche, W J Sandborn, B G Feagan, et al.
Alimentary Pharmacology & Therapeutics|November 17, 2015
A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variablesC A Siegel, H Horton, L S Siegel, et al.
Gastroenterology|August 28, 1999
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study GroupW J Sandborn, W J Tremaine, D C Wolf, et al.
Gastroenterology|January 1, 1997
A new syndrome of Crohn's disease and pachydermoperiostosis in a familyR F Compton, W J Sandborn, H Yang, et al.
International Journal of Obesity (2005)|May 11, 2016
Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptorD Hoang-Yen Tran, D Hoang-Ngoc Tran, S A Mattai, et al.
Nature Communications|August 10, 2016
A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitisManuel A Rivas, Daniel Graham, Patrick Sulem, et al.
Pageof 12